Vitality Biopharma Inc (OTCMKTS:VBIO) Cannabinoids Take on “Superbug”

Vitality Biopharma Inc (OTCMKTS:VBIO) Cannabinoids Take on “Superbug”

SHARE

Vitality Biopharma Inc (OTCMKTS:VBIO) treats serious neurological and inflammatory disorders for the treatment of microbes and other “superbug” pathogens. They recently applied for patents utilizing and unlocking the power of cannabinoids. Shares have followed a similar pattern for the cannabis sector with an upstart rally followed by a pulling back leaving price volatility and volume spurts. VBIO shares remain liquid even on slower days.

But a look at the chart shows prices rallying from under $1.00 (.85 cents) to $4.25 into year-end, then falling back to as low as $1.25 this year so far. Again, shares have been volume doubling on the upside quickly and then falling like a stone. Keep in mind, much of the cannabis sector has been performing this way.

Vitality Biopharma Inc (OTCMKTS:VBIO) is a company dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. VBIO recently announced that they have obtained positive results demonstrating antimicrobial activity of cannabinoids and filed for patent protection on the use of cannabinoid compounds for the treatment of microbes including Clostridium difficile and other “superbug” pathogens.

Utilizing a list of the top drug-resistant pathogens from the United States Centers for Disease Control and Prevention (CDC), Vitality researchers screened for antimicrobial activity in their portfolio of compounds. VBIO discovered new antimicrobial activities for cannabinoids. As a result, they filed for patent protection on the use of cannabinoids and cannabinoid prodrugs for the treatment of multiple pathogenic bacterial infections.

Find out when $VBIO stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

At the top of the CDC’s list is Clostridium difficile (C. diff), which is classified as an urgent threat to human health. The CDC reported in 2015 that it infected almost 500,000 Americans and was directly responsible for 15,000 deaths. VBIO successfully demonstrated antimicrobial reactivity of a cannabinoid against C. diff, and is currently conducting follow-on studies designed to enable pharmaceutical use of their targeted cannabinoid prodrugs for this application.

Vitality Biopharma Inc (OTCMKTS:VBIO) also confirmed that cannabinoids have antimicrobial activity towards methicillin-resistant Staphylococcus aureus (MRSA). The pathogen that was recently listed on the World Health Organization’s (WHO) list of priority pathogens posing a significant threat to human health globally. Additional antimicrobial activity was seen towards other antibiotic-resistant bacterial species that were included on the CDC and WHO lists. VBIO is seeking broad intellectual property coverage for use of cannabinoids against these pathogens as well.

“Our cannaboside prodrugs enable the targeted delivery of cannabinoids into the large intestine, where C.diff infections colonize, take over, and can cause severe damage. Our compounds are uniquely suited for performing this task, and it’s now clear they may provide benefits to gut health through multiple mechanisms,” said Dr. Brandon Zipp, Director of R&D at Vitality. Robert Brooke, the Company’s CEO, adds that, “This is a logical extension of our work that has been focused on gastrointestinal disease, and represents a new opportunity to treat a serious and life-threatening condition.”

The challenge from a technical standpoint is getting shares in Vitality Biopharma, Inc. (OTCMKTS: VBIO) to close above the current highs for the year. They seem to be turning higher and have made a few runs at this $3.30 level, but you need multiple closes above this price. As mentioned, the volume has been good so liquidity always adds more players.

VBIO is also driven by news in addition to the sector volume itself, so these shares are ones to keep an eye on in cannabis. They are aiming at serious pathogens and are pointed in the right direction establishing an important place in a sector that has huge upside – which medical cannabis surely does.

The current market-cap for VBIO is $38.18M and they are looking like an undervalued stock with serious pharmaceutical substance. VBIO could not only be an exciting story, but a real revenue stream for investors. For continuing coverage on shares of $VBIO stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

 

Sign Up for our 100% FREE Oracle Dispatch Newsletter